抗EGFR治疗与低镁血症  

Anti-EGFR therapy and hypomagnesemia

作　　者：缪若羽[1] 李龙芸[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院呼吸内科,北京100730

出　　处：《癌症进展》2008年第3期250-254,249,共6页Oncology Progress

摘　　要：表皮生长因子受体(EGFR)在多种上皮来源的正常细胞和恶性肿瘤细胞中表达,调节影响细胞增殖、分化和凋亡的信号途径。目前用于抑制EGFR家族的药物有两类:小分子酪氨酸激酶抑制剂(TKI)和单克隆抗体(MAb)。cetuximab是一种选择性结合EGFR的嵌合IgG1型单抗;而panitumumab则是第一个完全人源性的针对EGFR的IgG2型单抗。无论是单独给药还是与其他化疗药物联合,两者均表现出有效的抗肿瘤活性。与其他以EGFR途径为靶点的药物不同的是,低镁血症是两者较为常见而独特的副作用。本文回顾总结关于两者与低镁血症之间关系的病例报道和临床研究,并讨论这种相关性的可能解释及意义。EGFRs are expressed on the surface of a variety of epithelia-derived cells. Currently, two types of anti - EGFR agents, [ the small molecular tyrosine kinase inhibitors （TKIs） and the other monoclonal antibodies （MAbs） ] are available. Cetuximab （Erbitux） is an IgG1 - typed chimic MAb that selectively binds EGFR, while panitumumab （ABX- EGF） is the first IgG2 -typed human MAb that targets EGFR. Both of them have been effective in anti - cancer therapy either as monotherapy or in combination with other chemotherapeutic agents. In contrast to other anti -EGFR agents, hypomagnesemia has been their common and unique side effect. This review summarizes the case reports and clinical studies that made an association between cetuximab/panitumumab therapy and the incidence of hypomagnesemia, and discusses the possible explanation and significance of their relationship.

关 键 词：CETUXIMAB PANITUMUMAB 表皮生长因子受体 低镁血症 

分 类 号：R730.54[医药卫生—肿瘤]